The aim of this analysis was to investigate the relationships between dyslipidemia, achieved blood pressure (BP) values and the lipid levels, as well as the control of four cardiovascular risk factors (BP, low-density lipoprotein: LDL cholesterol, hemoglobin A1c: HbA1c and smoking) and the incidence of cardiovascular disease (CVD), in Japanese patients receiving antihypertensive therapy. Methods: A total of 13,052 patients with no history of CVD were included in this subanalysis of the prospective observational OMEGA study in Japanese hypertensive patients treated with olmesartan. Multivariable Cox regression models were used to evaluate the relationship with the risk of CVD. Results: The incidence of CVD during the 36-month study period was 5.59/1,000 patient-years among the patients with dyslipidemia (n 6,297) and 5.57/1,000 patient-years among the patients without dyslipidemia (n 6,755), with no significant differences between the two groups. Higher achieved BP values tended to be associated with an increased CVD risk in both the patients with and without dyslipidemia. In addition, the risk of CVD tended to be higher in the patients with an achieved LDL cholesterol level of ≥ 120 mg/dL than in those with an LDL level of 120 mg/dL (trend p 0.0005) and in the patients with an achieved high-density lipoprotein cholesterol level of 60 mg/dL than in those with an HDL level of ≥ 60 mg/dL (trend p 0.0017). Furthermore, the risk of CVD was higher among the patients with fewer controlled risk factors than among those with control of all four risk factors (trend p 0.0001). Conclusions: In order to prevent CVD in olmesartan-treated hypertensive patients with no history of CVD, it is important to control both the lipid and BP levels and aim for comprehensive risk factor control.
Introduction
Atherosclerotic cardiovascular disease (CVD) is a leading underlying cause of death in Japan, whose population is aging rapidly. Therefore, effective strategies for preventing CVD are urgently needed.
One such strategy is to aggressively control both dyslipidemia and hypertension. Dyslipidemia is an important risk factor for CVD, and epidemiologic studies have shown that higher low-density lipoprotein (LDL) cholesterol 1) and non-high-density lipoprotein (HDL) cholesterol levels 2) and lower HDL between the incidence of CVD and dyslipidemia, achieved BP and the lipid levels in patients with no history of CVD using data obtained from the OMEGA study. The relationship between the comprehensive control of four CVD risk factors (BP, LDL cholesterol, HbA1c and smoking) and the incidence of CVD was also analyzed.
Methods
The OMEGA study was conducted as a prospective, large-scale observational study from July 2005 to March 2010 by Sankyo Co., Ltd. (presently Daiichi Sankyo Co., Ltd.). The study protocol was approved by the Ethics Committee of Sankyo Co., Ltd., as well as the Ministry of Health, Labour and Welfare of Japan before commencement, and conformed with the pharmaceutical affairs laws of Japan. Furthermore, the study conformed to the Helsinki Declaration of 1975 as revised in 1983 and was carried out at registered medical institutions according to Good Postmarketing Study Practices in Japan. The survey data were collected via the Internet using a validated electronic data-capturing system (PostMaNet; Fujitsu FIP, Tokyo, Japan). The protocol for the OMEGA study is described briefly below. Further details of the protocol are available in a previous publication 16) .
Patients
Male and female outpatients 50-79 years of age with essential hypertension who had not been previously treated with olmesartan were enrolled in the OMEGA study. The exclusion criteria were a history of myocardial infarction, stroke, coronary artery bypass grafting or percutaneous coronary intervention within six months prior to enrollment, as well as scheduled coronary intervention, congenital or rheumatic heart disease, severe arrhythmia, severe hepatic or renal disease, cancer that was currently under treatment and pregnancy or the potential to become pregnant.
The patients were enrolled using the central registration system. Written informed consent was obtained from each patient, and a questionnaire survey regarding lifestyle and habits was conducted prior to the start of the study. This subanalysis was carried out in order to investigate the incidence of initial CVD in patients without a history of the disorder.
Observation Items and Period
The observation items included the following information: patient characteristics, lifestyle factors and habits; exposure to olmesartan and concomitant cholesterol levels [3] [4] [5] are associated with an increased incidence of coronary heart disease (CHD). Another important risk factor for CVD is hypertension. Hypertension is closely related to cerebrovascular disorders 6, 7) ; individuals with higher blood pressure (BP) values are more likely to develop cerebrovascular diseases 8, 9) . Furthermore, the coexistence of dyslipidemia and hypertension increases the risk of arteriosclerosis 4) . Among hypercholesterolemic patients with hypertension, aggressive LDL cholesterol-lowering treatment may prevent the incidence or recurrence of ischemic heart disease and stroke 10) . In addition, diet therapy combined with pravastatin treatment is effective in the primary prevention of CVD, reducing the risk of cerebral infarction by 46%, in Japanese patients with mild-to-moderate dyslipidemia complicated by hypertension 11) . However, few reports have addressed the relationship between the achieved BP value, lipid levels and incidence of CVD in Japanese patients in clinical practice.
The Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases recommend the comprehensive control of dyslipidemia, hypertension and other risk factors, such as diabetes mellitus and smoking, in order to prevent atherosclerotic disease 12) . However, few reports have addressed the relationship between comprehensive risk factor control and the incidence of CVD in Japanese patients in clinical practice.
The Olmesartan Mega Study to Determine the Relationship Between Cardiovascular Endpoints and Blood Pressure Goal Achievement (OMEGA study) is a large-scale prospective observational study designed primarily to evaluate the relationships between the achieved BP, metabolic syndrome, lifestyle factors (e.g. dietary habits), other risk factors and the incidence of CVD in Japanese hypertensive patients treated with olmesartan medoxomil. We previously reported the relationships between the achieved BP, dietary habits, metabolic syndrome and the incidence of CVD 13) . In addition, we reported that diabetes mellitus is an important risk factor for CVD, cerebrovascular events (stroke) and CHD and that dyslipidemia is an important risk factor for CHD 14) . In addition, previous reports have described the relationships between diabetes mellitus, achieved BP, hemoglobin A1c (HbA1c, National Glycohemoglobin Standardization Program) and the incidence of CVD 15) .
Aim
Our aim was to investigate the relationships the dyslipidemia and non-dyslipidemia groups), body mass index and smoking as adjusted factors. BP was classified using cut-off values of 130/85 mmHg and 140/90 mmHg, in accordance with the JSH 2009 criteria 17) . In the analyses of the relationships between the lipid levels and the risk of CVD, the achieved BP value was also applied as a time-dependent adjusted factor. The lipid levels were classified using the following cut-off values: LDL cholesterol 120 mg/dL, 140 mg/dL and 160 mg/dL, and HDL cholesterol 40 mg/dL and 60 mg/dL, in accordance with the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012 12) . The relationship between comprehensive risk factor control and the risk of CVD was evaluated using the Cox proportional hazards model, including each risk factor (LDL cholesterol, BP, HbA1c and smoking) or the number of controlled risk factors as covariates, adjusted for sex, age, family history of coronary arthery disease and body mass index.
The degree of control of LDL cholesterol (adequately controlled: 120 mg/dL), BP (adequately controlled: 140/90 mmHg) and HbA1c (adequately controlled: 6.9%) was assessed based on the mean measurements obtained during the study period. The degree of control of smoking (adequately controlled: non-smoking) was assessed based on the results of the patient questionnaire obtained at baseline, which classified patients as either 'non-smokers' (including subjects who answered 'never smoked' or 'quit smoking more than one year ago') or 'smokers' (including subjects who answered 'quit smoking within the past year' or 'currently smoking'). Since almost half of the study patients were elderly, the target BP for elderly patients defined by the JSH 2009 criteria 17) ( 140/90 mmHg) was used as a target.
All statistical analyses were performed using the SAS version 9.2 software program (SAS Institute Inc., Cary, NC, USA), with a two-sided significance level of 0.05.
Results

Patients
A total of 15,313 patients were enrolled from 2,219 institutions across Japan, and baseline data for 15,255 patients were collected. Of these individuals, 534 were excluded: 51 patients who were later found to not have met the inclusion or exclusion criteria, six patients who received no dose of olmesartan, 244 patients for whom no on-treatment data were available (e.g. those who did not return to the institution after their first visit), 82 patients with no case report drugs; concomitant therapies; BP; pulse rate; laboratory results; and incidence of CVD. The observation period was three years from the start of treatment with olmesartan. Observation was continued even if the olmesartan treatment was discontinued and terminated if a patient was lost to follow-up or withdrew their consent. The method of BP measurement was not specified, and the BP values were obtained according to the routine procedures used at each institution. Data for the BP, pulse rate and laboratory tests were collected before study initiation and every six months thereafter. If available, any applicable values measured in daily clinical practice during the study period were also collected.
Events
Cardiovascular disease was defined as a composite of the following events: stroke (cerebral infarction, cerebral hemorrhage or subarachnoid hemorrhage), CHD (myocardial infarction, cardiac intervention or hospitalization for angina) and sudden death. CVD was defined as a composite endpoint comprising the above three endpoints.
The diagnostic criteria for the various endpoints have been previously described in detail 13, 16) .
Definition of Dyslipidemia
In this subanalysis, patients who met either of the following conditions were considered to have dyslipidemia and those who met neither condition were considered to be without dyslipidemia: patients who had been diagnosed by their physician as having dyslipidemia at the start of the study and those who were receiving treatment with any lipid-lowering drugs at the start of the study.
Statistical Analysis
The patient characteristics of the dyslipidemia and non-dyslipidemia groups were compared using the t -test for continuous variables and the chi-squared test for categorized variables. Data for BP, LDL cholesterol and HDL cholesterol were analyzed by comparing the values obtained at baseline and each visit using the Dunnett-Hsu test. The incidence of CVD during the study period was compared between the dyslipidemia and non-dyslipidemia groups using the log-rank test. The relationships between the achieved BP values and lipid levels and the risk of CVD were evaluated using the Cox proportional hazards model, including the achieved BP values or lipid levels as time-dependent covariates and sex, age, family history of coronary arthery disease, HbA1c (time-dependent covariate), dyslipidemia (only in comparisons between years.
Exposure to Olmesartan and Concomitant Drugs
The daily dose of olmesartan at baseline was 17.2 5.6 mg in the dyslipidemia group versus 17.3 5.4 mg in the non-dyslipidemia group. At 36 months, the daily doses were 17.3 8.6 mg and 17.2 8.3 mg, respectively. The proportion of patients who were still receiving treatment with olmesartan at 36 months was similar between the dyslipidemia group and non-dyslipidemia group (91.3% and 90.9%, respectively).
The proportion of patients who received any antihypertensive drugs other than olmesartan prior to the start of the survey was 53.3% in the dyslipidemia group and 43.6% in the non-dyslipidemia group. Meanwhile, the number of antihypertensive drugs, including olmesartan, used at baseline and at 36 months was similar between the groups (1.5 0.7 and 1.6 0.9, respectively, in the dyslipidemia group, compared with 1.4 0.7 and 1.6 0.9, respectively, in the non-dyslipidemia group). Table 2 shows the rate of use of olmesartan and concomitant antihypertensive drugs at baseline, after six months and at study completion. The percentage of patients taking olmesartan was similar between those with and without dyslipidemia at all time points. The percentage of patients taking antihypertensive drugs other than olmesartan increased by approximately 10% after six months and approximately 15% at study completion, compared form data at six months, 63 patients who withdrew their consent during the first six months of the study and 88 patients who were later found to have enrolled after the specified period of enrollment. Of the remaining 14,721 patients, 13,052 had no history of CVD, and their data were accordingly included in the subanalysis (Fig. 1) .
Patient Characteristics
The patient characteristics at baseline are summarized in Table 1A . A total of 6,297 patients (48.2%) had dyslipidemia. The proportion of women was higher in the dyslipidemia group than in the non-dyslipidemia group. However, there were no differences in age between the two groups. In the dyslipidemia group, the duration of hypertension was significantly longer, although the systolic BP (SBP) and diastolic BP (DBP) values were both lower. Meanwhile, the LDL cholesterol and non-HDL cholesterol values were higher in the dyslipidemia group, whereas the HDL cholesterol values were similar between the groups. In addition, the patients with dyslipidemia were more likely to have diabetes mellitus and hepatic and/or renal impairment. The changes in the LDL and HDL cholesterol levels from baseline to 36 months in the dyslipidemia and non-dyslipidemia groups are shown in Fig. 3 .
with that observed at baseline among the patients with and without dyslipidemia.
The proportion of dyslipidemic patients using any lipid-lowering drugs slightly increased from baseline (41.7%) to 36 months (53.7%). Most of the lipid-lowering drugs used during the study period were statins (35.3% at baseline and 46.0% at 36 months). In the non-dyslipidemia group, the proportion of patients who used any lipid-lowering drugs at 36 months was 7.9% (statins: 6.5%).
Changes in Blood Pressure and Lipid Levels
The changes in BP from baseline to 36 months in the dyslipidemia and non-dyslipidemia groups are shown in Fig. 2 . The SBP/DBP values in the dyslipid- 
Incidence of Cardiovascular Disease
The incidence of CVD, stroke and CHD during the study period was 5.59, 2.40 and 3.29 per 1,000 patient-years, respectively, in the dyslipidemia group, and 5.57, 3.06 and 2.11 per 1,000 patient-years, respectively, in the non-dyslipidemia group. The rate of CHD differed significantly between the two groups (p 0.0323), whereas the frequency of CVD and Consequently, the LDL cholesterol levels in the dyslipidemia group were significantly decreased at 36 months (115.6 27.9 mg/dL) compared to that observed at baseline (131.5 35.1 mg/dL, p 0.0001). The LDL cholesterol levels in the non-dyslipidemia group also decreased significantly from baseline (114.8 27.0 mg/dL) to 36 months (111.7 25.8 mg/dL, p 0.0001); however, the difference was smaller than that seen in the dyslipidemia group. In contrast, the high-density cholesterol levels did not change significantly during the study period in either the dyslipidemia group (58.0 15.8 mg/dL at baseline and 58.0 found between the dyslipidemia and non-dyslipidemia groups (p 0.4367).
The relationships between the achieved BP values and/or lipid levels and the risk of CVD were evaluated in the primary prevention population comprising both the dyslipidemia and non-dyslipidemia groups (Fig. 4) . Compared with that observed in the 130/85 mmHg (based on the on-treatment BP values) group, the risk of CVD was higher in the 130/ 85 and 140/90 mmHg groups (hazard ratio, HR, stroke did not (p 0.9733 and p 0.2436, respectively) ( Table 3) .
Relationships between Blood Pressure, the Lipid Levels and the Risk of Cardiovascular Disease
The relationship between the achieved BP values and the risk of CVD was evaluated in the dyslipidemia and non-dyslipidemia groups ( Table 4) . Consequently, no interactions for the relationship between the achieved BP value and the incidence of CVD were achieved lipid levels (LDL cholesterol, HDL cholesterol and non-HDL cholesterol) and the risk of CVD showed that higher LDL cholesterol and non-HDL cholesterol levels and lower HDL cholesterol levels tended to be associated with a higher CVD risk, even Table 6 ). In the group with three controlled risk factors, only 50.3% of the patients achieved control of LDL cholesterol; this proportion was lower than that for all other risk factors (77.0-89.2%) (Fig. 5) .
after adjusting for the achieved BP value (trend p 0.0005, 0.0017 and 0.0002, respectively).
Comprehensive Risk Factor Control
The relationships between adequate or inadequate control of each CVD risk factor (LDL cholesterol, BP, HbA1c and smoking) and the risk of CVD were evaluated in the primary prevention population (Table 5) . Consequently, the CVD risk was significantly higher among the patients with inadequately LDL cholesterol, BP and/or HbA1c values. On the other hand, no significant differences in the risk of CVD were found between non-smokers (risk factor adequately controlled) and smokers (risk factor inadequately controlled).
The relationship between the number of adequately controlled risk factors and the risk of CVD Covariates: dyslipidemia, BP during the observation period (time-dependent covariate), sex, age, family history of coronary artery disease, HbA1c (time-dependent covariate), body mass index and smoking habits. patient baseline characteristics according to the comprehensive risk factor control category showed no major differences in age, body mass index, duration of hypertension or coexisting diseases, factors that were not included in the assessment of comprehensive risk factor control.
In both the dyslipidemia group and the non-dyslipidemia group, the BP values were decreased significantly at six months compared with that observed at baseline, and the significantly lower BP values were maintained at 36 months. This finding highlights the long-term antihypertensive effect of olmesartan-based treatment, regardless of whether dyslipidemia is present.
The low-density lipoprotein cholesterol levels in the dyslipidemia group were also significantly decreased at 36 months, which may have partly resulted from the slight increase in the proportion of patients using lipid-lowering drugs. This finding shows that the patients with dyslipidemia had appropriate lipid control. Furthermore, the LDL cholesterol levels were sig-
Discussion
Using data from the OMEGA study, we investigated changes in BP and the lipid levels in patients with and without dyslipidemia, as well as the incidence of CVD in patients with and without dyslipidemia, the relationships between the achieved BP values and lipid levels and the risk of CVD and the relationship between comprehensive risk factor control and the risk of CVD.
The comparisons of the patient characteristics between the dyslipidemia group and the non-dyslipidemia group showed that the dyslipidemic patients were more likely to have had diabetes mellitus and hepatic and/or renal impairment. These findings suggest that hypertensive patients with dyslipidemia exhibit greater accumulation of CVD risk factors. In the dyslipidemia group, the duration of hypertension was longer and the patients were more likely to have used at least one antihypertensive drug prior to the start of the study. In addition, the comparisons of the non-dyslipidemia group, whereas that of CHD was significantly higher in the dyslipidemia group. Even among the patients with dyslipidemia, who are expected to be at increased risk of cardiovascular events, the incidence of CVD was lower than expected. The low incidence of CVD may be attributed to the widespread use of angiotensin receptor blockers as first-line therapy, the implementation of revised guidelines recommending strict BP control and improvements in the medical environment as well as the treatment of complications of hypertension, such as dyslipidemia.
Moreover, among the patients with dyslipidemia, 35.3% were treated with statins and demonstrated significantly decreased in the non-dyslipidemia group, although the decrease was smaller than that noted in the dyslipidemia group. In contrast, the HDL cholesterol levels did not change significantly in either the dyslipidemia group or the non-dyslipidemia group.
The incidence of CVD in the OMEGA study was 281/14,721 patients (7.15/1,000 patient-years) 13) , which is lower than that assumed prior to the start of the study (435/9,710 patients, 15/1,000 patient-years) 16) . The incidence of CVD in this subanalysis was 95/ 6,297 patients (5.59/1,000 patient-years) in the dyslipidemia group and 100/6,755 patients (5.57/1,000 patient-years) in the non-dyslipidemia group. The incidence of stroke was significantly higher in the an increased CVD risk, which suggests that the BP value should be decreased to at least ≤ 140/90 mmHg. Furthermore, the evaluation of the relationship between the lipid levels and the risk of CVD in the primary prevention population showed that the deterioration of lipid endpoints is associated with an increased CVD risk. Moreover, we conducted a subanalysis of the dyslipidemia group only. Similar to the results of the analysis of the primary prevention population, an increased lipid level was found to be associated with an increased CVD risk. However, the increase in HR was greater than that observed in the primary prevention population [LDL cholesterol: HR vs 120 mg/ dL; 1.919 (≥ 120 mg/dL to 140 mg/dL), 2.630 (≥ 140 mg/dL to 160 mg/dL), 2.861 (≥ 160 mg/dL), trend p 0.0033; non-HDL cholesterol: HR vs 150 mg/dL; 2.053 (≥ 150 mg/dL to 170 mg/dL), 2.430 (≥ 170 mg/dL to 190 mg/dL), 3.427 (≥ 190 mg/dL), trend p 0.0006]. This finding emphasizes the importance of controlling the lipid levels, as well as BP, in hypertensive patients.
The association between comprehensive risk factor control and the risk of CVD was also evaluated. The assessed CVD risk factors included BP, HbA1c and LDL cholesterol, which by themselves are important risk factors for CVD, as well as smoking. Our nificant improvements in the LDL cholesterol levels without changes to the HDL cholesterol levels, indicating appropriate management of the lipid profiles. We consider that this observation may have led to a reduction in the risk of CVD among the patients with dyslipidemia, who are considered to be at high risk of CVD.
It has also been reported that an increase in BP is associated with a significantly greater CVD risk in patients with dyslipidemia 11, 18) . In the present study, a sustained antihypertensive effect of olmesartan was found in the patients with dyslipidemia, suggesting that the antihypertensive effects of the RAS inhibitor olmesartan 19) may have helped to prevent CVD in this group of patients. Furthermore, it is possible that effects of the RAS inhibitor other than its antihypertensive effects, such as anti-inflammatory effects 20) and/or prevention of the progression of coronary atherosclerosis 21) , may have contributed to the preventive effects against CHD observed in the hypertensive patients with dyslipidemia; however, further studies are needed to verify this speculation.
The analysis of the relationship between the achieved BP values and the risk of CVD in the primary prevention population showed that an increased BP (i.e. a higher achieved BP value) is associated with HbA1c and smoking in order to prevent CVD. Lipid abnormalities, in particular, constitute a residual risk factor in many hypertensive patients. Therefore, controlling lipids, as well as BP and HbA1c, is necessary in order to achieve comprehensive control of the risk of CVD. evaluation showed that having fewer controlled risk factors markedly increases the risk of CVD, underlining the importance of achieving comprehensive control of CVD risk factors. The HR for CVD was higher among the patients in whom three of four factors were adequately controlled, while the remaining factor was inadequately controlled, than for the patients who attained adequate control of all four risk factors. When the achievement of control was evaluated according to each risk factor, only half of the patients achieved control of LDL cholesterol. The OMEGA study was an observational study. Therefore, the results of this subanalysis suggest that many hypertensive patients have poorly controlled dyslipidemia in clinical practice and that achieving lipid control, in addition to BP and HbA1c control, is necessary for obtaining comprehensive risk factor control in hypertensive patients.
The present subanalysis, in which data from a single-arm observational study of hypertensive patients receiving olmesartan were retrospectively stratified and analyzed, is associated with various limitations. In the OMEGA study, the patients were treated by their primary physician based on their individual characteristics and condition, with no prespecified targets for BP or the lipid levels. Therefore, the relationships between the achieved BP values and/or lipid levels and the risk of CVD may have been confounded by unmeasured factors other than those chosen as factors for adjustment. With respect to smoking, the results of the baseline questionnaire were used for the analyses, as changes in smoking habits during the study period were not investigated.
Despite these limitations, the results of the present subanalysis are useful for application in clinical practice because angiotensin receptor blockers, such as olmesartan, are prescribed extensively to treat hypertension. Furthermore, we used data obtained from a large-scale study showing the therapeutic effects of olmesartan in hypertensive patients with various characteristics in real-world clinical practice.
Conclusion
In conclusion, this subanalysis of the OMEGA study showed that olmesartan-based treatment achieves a good antihypertensive effect in hypertensive patients with or without dyslipidemia and that adequately controlling lipids, in addition to BP, is important for the primary prevention of CVD in hypertensive patients with or without dyslipidemia.
The results of this subanalysis also emphasize the importance of comprehensively controlling BP, lipids,
